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ABSTRACT: We report the synthesis and biological
evaluation of a series of 7-aryl-1,2,4-triazolo[4,3-a]pyridines
with mGlu2 positive allosteric modulator (PAM) activity and
aﬃnity. Besides traditional in vitro parameters of potency and
aﬃnity, kinetic parameters kon, koff and residence time (RT)
were determined. The PAMs showed various kinetic proﬁles;
kon values ranged over 2 orders of magnitude, whereas RT
values were within a 10-fold range. Association rate constant
kon was linearly correlated to aﬃnity. Evaluation of a short,
medium, and long RT compound in a label-free assay indicated
a correlation between RT and functional eﬀect. The eﬀects of
long RT compound 9 on sleep−wake states indicated long RT
was translated into sustained inhibition of rapid eye movement (REM) in vivo. These results show that aﬃnity-only driven
selection would have resulted in mGlu2 PAMs with high values for kon but not necessarily optimized RT, which is key to
predicting optimal eﬃcacy in vivo.
■ INTRODUCTION
Glutamate is an important neurotransmitter in the human central
nervous system (CNS), where it modulates synaptic responses
by activating ionotropic glutamate receptors (iGlu) and
metabotropic glutamate receptors (mGlu).1 The eight known
mGlu receptors, which belong to the class C G-protein-coupled
receptors (GPCRs), have been divided into three subclasses
based on sequence homology, signaling pathway, and
pharmacological proﬁle: group I (mGlu1,5), group II (mGlu2,3),
and group III (mGlu4,6,7,8).
2 Structurally, class C GPCRs consist
of a large extracellular orthosteric binding domain, the so-called
Venus ﬂytrap (VFT), a cysteine-rich domain connecting the VFT
to the seven-transmembrane (7TM) domain.2,3 Group II mGlu
receptors are coupled to the Gαi/o protein and are generally
expressed presynaptically in the periphery of the synapse where
they inhibit the release of glutamate upon activation.4 The
activation of mGlu2 receptors has been shown to be a potential
strategy for the treatment of psychiatric diseases involving
abnormal glutamatergic neurotransmission, such as schizophre-
nia and anxiety disorder.5,6 Drug discovery eﬀorts include the
development of positive allosteric modulators (PAMs) for which
subtype selectivity can be more easily obtained as they bind
within the less conserved 7TM domain and have little or no
intrinsic activity on their own.7,8 The mGlu2 PAMs N-(4-(2-
methoxyphenoxy)phenyl)-N-(2,2,2-triﬂuoroethylsulfonyl)-
pyrid-3-ylmethylamine (1, LY487379),9 biphenylindanone A (2,
BINA),10 N-(4-((2-(triﬂuoromethyl)-3-hydroxy-4-(isobutyryl)-
phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxa-
mide (3, THIIC, also known as LY2607540),11 and 3-cyano-1-
cyclopropylmethyl-4-(4-phenylpiperidin-1-yl)pyridine-2(1H)-
one (4, JNJ-40068782)12 (Figure 1) have been characterized
both in vitro and in vivo. To date, twomGlu2 PAMs have reached
clinical trials. The development of 7-methyl-5-[3-(piperazin-1-
ylmethyl)-1,2,4-oxadiazol-5-yl]-2-[[4-(triﬂuoromethoxy)-
phenyl]methyl]-3H-isoindol-1-one (5, AZD8529) by AstraZe-
neca was discontinued after a phase 2 schizophrenia trial in which
it did not show clinical eﬃcacy when tested as monotherapy.13,14
Compound 5 recently ﬁnished a phase II clinical trial to study
smoking cessation in female smokers.15
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Meanwhile, the Janssen/Addex mGlu2 PAM 1-butyl-3-chloro-
4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (6, JNJ-40411813/
ADX71149) met the primary objectives of safety and tolerability
in an exploratory phase IIa study in schizophrenia. Moreover,
patients treated with antipsychotics who experience residual
negative symptoms were identiﬁed as the subgroup that may
potentially beneﬁt from add-on treatment with 6, although this is
yet to be established in a formal proof-of-concept study. In
addition, in a second phase IIa study with 6 as adjunctive therapy
in patients having major depressive disorder (MDD) with
signiﬁcant anxiety symptoms, 6 did not meet the criterion for
eﬃcacy vs placebo. Although 6 showed eﬃcacy signals on several
Figure 1. Structures of reference mGlu2 PAMs. The position of the tritium label of [
3H]-7 is denoted by ∗.
Scheme 1. Synthesis of Final Compounds 8−48a
aReagents and conditions: (a) Pd(PPh3)4, NaHCO3, H2O/1,4-dioxane, 150 °C, 5−30 min, microwave.
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anxiety and depression measures, the primary end point was not
met and overall the results did not suggest eﬃcacy for 6 as an
adjunctive treatment for patients with MDD with signiﬁcant
anxious symptoms.16−22
To understand more about the key in vitro parameters that
could drive in vivo eﬃcacy, we have focused on the ligand
binding kinetics in addition to more classical in vitro parameters.
It is now becoming increasingly apparent that in vivo eﬃcacy can
depend on optimized kinetic behavior.23 Indeed, in the past
decade the concept of ligand binding kinetics has received an
increasing amount of interest.24−27 Both the association and
dissociation rate constants kon and koff have been studied for
various drug targets including GPCRs.28 The relevance of
residence time (RT), deﬁned as the reciprocal of the dissociation
rate constant (RT = 1/koff), for in vivo eﬃcacy was
retrospectively shown for multiple marketed GPCR drugs,
such as the long acting M3 receptor antagonist tiotropium and
fast dissociating D2 antagonists with lower side-eﬀect bur-
den.29−31 Whereas dissociation rates have been the focus of most
kinetic studies, association rates have also been described to be
important for fast drug action and high receptor occupancy.32−34
Here, we report the synthesis and biological evaluation of a
novel series of 7-aryl-1,2,4-triazolo[4,3-a]pyridines, which
evolved from a pyridone series (4 and 6) through a scaﬀold
hopping drug-design strategy previously described.35,36 These
compounds were characterized as mGlu2 PAMs in a functional
assay, and additionally, radioligand binding experiments were
performed to determine their aﬃnity and kinetic binding
parameters. We demonstrate that the diﬀerentiated binding
kinetics result in a varied response in a label-free assay on whole
cells. In this way we have been able for the ﬁrst time to obtain
both structure−activity/aﬃnity relationships and structure−
kinetic relationships for a class C GPCR.
■ CHEMISTRY
The target compounds 8−48 were prepared via Suzuki cross
coupling of the corresponding 7-halotriazolopyridines (49a,b;
50a−c; and 51a,b) with an array of boronic esters (52a−v) as
shown in Scheme 1. The chemical structures of compounds 8−
48 are shown in Tables 3−6).
The key 7-halotriazolopyridines (49a,b; 50a−c; and 51a,b)
and noncommercially available boronic esters (52a−v) were
prepared following the procedures previously described.37,38
■ BIOLOGY
The potency of the compounds was determined by quantifying
the increase in response of a ﬁxed EC20 glutamate concentration
(4 μM) observed in a functional [35S]GTPγS binding assay. The
aﬃnity of all compounds was determined in a full curve
radioligand displacement assay in the presence of 6 nM of the
mGlu2 PAM 3-(cyclopropylmethyl)-7-[(4-phenyl-1-
piperidinyl)methyl]-8-(triﬂuoromethyl)-1,2,4-triazolo[4,3-a]-
pyridine (7, JNJ-46281222), which was radioactively labeled with
tritium.39 In order to determine the kinetic parameters kon and
koff, we performed a radioligand competition association assay
characterized by the equations of Motulsky and Mahan that
describe the binding between two ligands competing for the
same receptor binding site.40 For this purpose, ﬁrst the
association rate constant kon and dissociation rate constant koff
of 7 were determined in radioligand association and dissociation
experiments using a scintillation proximity assay (SPA).41
Kinetic parameters were determined at 28 °C; presumably
these will increase at 37 °C. All kinetic assays were performed in
the presence of 1 mM glutamate; this condition induced a
monophasic association process of the PAM, which is required
for the determination of the kinetic parameters of unlabeled
PAMs.39 The presence of glutamate was shown to not aﬀect
aﬃnity and kinetic parameters of 7.39 Ultimately, three
compounds with representative RT values were selected for
comparison in a label-free, impedance based assay (xCELLi-
gence) which measures ligand-induced responses on whole cells.
This assay provided further understanding of the inﬂuence of RT
on the duration of PAM-induced receptor activation.
■ RESULTS AND DISCUSSION
Kinetic rate constants kon and koff for 7 were similar when
obtained in the association and dissociation assays compared to
the competition association assay (Table 1), which validated the
use of the competition association assay for all other compounds.
Kinetic KD values were comparable to the values reported
before.39
Reference mGlu2 PAMs 2−5 (Table 2) showed moderate to
good potency and aﬃnity at the mGlu2 receptor, in agreement
with previous reports.39,42,43 Kinetic parameters kon, koff, and RT
were also determined. Reference compound 2was shown to have
a RT of 11.6 min. The other reference PAMs had RTs in the same
range, from 7.8 min for 5 to 17.3 min for 7 (Table 1).
Table 1. Comparison of Kinetic Parameters of 7 Determined by Two Diﬀerent Methodsa
assay KD (nM)
b kon (M
−1 min−1) koff (min
−1) RT (min)
association and dissociationc 1.1 ± 0.22 (7.1 ± 0.43) × 107 0.080 ± 0.015 12.5 ± 2.3
competition associationd 2.5 ± 0.71 (2.3 ± 0.60) × 107 0.058 ± 0.005 17.3 ± 1.6
aValues represent the mean ± SEM of at least three individual experiments performed in duplicate. bKinetic KD values, deﬁned as KD = koff/kon.
cAssociation and dissociation rate constants of [3H]-7 in a classical radioligand kinetic binding assay at 28 °C using SPA. dAssociation and
dissociation rate constants of 7 measured in a competition association assay at 28 °C using SPA.
Table 2. Functional Activity (pEC50), Aﬃnity (pKi), and Kinetic Parameters (kon, koff, RT) for Reference mGlu2 PAMs 2−5
compd pEC50 pKi
b kon (M
−1 min−1)c koff (min
−1)c RT (min)c,d KD (nM)
c,e
2 7.03 ± 0.14a 7.22 ± 0.15 (4.6 ± 2.3) × 106 0.086 ± 0.022 11.6 ± 2.9 190 ± 100
3 6.97 ± 0.08a 7.10 ± 0.04 (1.2 ± 0.38) × 106 0.120 ± 0.020 8.4 ± 1.4 100 ± 36
4 7.1 ± 0.1a 7.58 ± 0.08 (1.7 ± 0.70) × 106 0.090 ± 0.015 11.1 ± 1.9 51 ± 22
5 6.25 ± 0.06 6.43 ± 0.03 (2.1 ± 0.65) × 105 0.128 ± 0.040 7.8 ± 2.4 600 ± 260
aAs previously described by Farinha et al. (2015).42 bAs previously described by Doornbos et al. (2016).39 cValues represent the mean ± SEM of at
least three individual experiments. dRT = 1/koff.
eKinetic KD values, deﬁned as KD = koff/kon.
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The analysis of the triazolopyridines containing a substituted
pyridine (Table 3) began with elaboration of the R1 substitution.
Compound 8 was taken as the starting point. Substitution of
chlorine at the R1 position by triﬂuoromethyl (9) resulted in an
increase in potency, while aﬃnity remained the same.
Introduction of methyl (10) or isopropyl (11) led to an
approximately 10-fold decrease in aﬃnity and potency.
Interestingly both kon and RT values were similar for 8, 10,
and 11 but 2-fold (kon) and approximately 3-fold (RT) higher for
9. Substitution of ﬂuorine by chlorine at the R2 position resulted
in increased potency and aﬃnity for 12, 13, and 14. In both cases,
the PAMs with CF3 at R
1 (9 and 13) showed modestly longer
Table 3. Functional Activity (pEC50), Aﬃnity (pKi), and Kinetic Parameters (kon, koff, RT) for mGlu2 PAMs 8−23
aValues represent the mean followed by individual values in parentheses when of two experiments and the mean ± SEM when of three or more
experiments.
b,c,d,e,f
Values represent the mean ± SEM of at least three individual experiments, all performed in duplicate. eRT = 1/koff.
fKinetic KD
values, deﬁned as KD = koff / kon.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b00669
J. Med. Chem. 2017, 60, 6704−6720
6707
RTs of 30 and 23 min, respectively, along with highest potency
and aﬃnity.
Exploration of the pyridine R3 revealed the importance of the
position of the nitrogen. Compound 15 showed decreased
potency and aﬃnity compared to 8. A similar trend was seen for
16 that showed values comparable to those reported previously
which revealed decreased potency and aﬃnity compared to 9.42
Values for kon followed this trend, whereas RTs remained the
same for 15 but decreased from 30 to 11 min for 16.
Subsequently the alkyl substituents on the pyridine ring were
evaluated. Substitution of methyl in 15 by ethyl in 17 led to an
increased potency and aﬃnity. Addition of a methyl group on the
5-position of 16 did not change aﬃnity or potency in 18, nor
were large changes seen in kinetic parameters. Introduction of
the bulky and lipophilic isopropyl in 19 and 20 increased
potency, aﬃnity, and kon slightly. Interestingly, the RT of 20 was
reduced to only 5 min.
Substitution of the cyclopropylmethyl substituent at the R4
position by 2,2,2-triﬂuoroethyl (21) resulted in a slight decrease
in aﬃnity, similar values for potency and RT, and a 5-fold
increase in kon compared to 8. Next, the ethoxymethyl
substituent was evaluated at R4 (22), which yielded a slight
decrease in potency, a 10-fold decrease in kon, and similar values
for aﬃnity and RT compared to 21. Substitution of F in 22 by
CF3 at R
1 did not yield a drastic increase in aﬃnity and potency
(23). Together, 21−23 showed that a cyclopropylmethyl
substituent at R4 is preferred, as in all three cases the analogue
bearing cyclopropylmethyl at R4 showed a higher aﬃnity (8 or
9).
The structure of substituted pyridine of 8 was changed to the
short aliphatic isopropyl or cyclopropyl substituent, yielding 24−
30 (Table 4). Potency and aﬃnity of 24 were relatively low
(pEC50 = 6.65; pKi = 7.21). Changing the R
1 substituent to CF3
(25) increased aﬃnity and potency again (pEC50 = 7.03; pKi =
8.05). Substitution of the ﬂuorine on R2 to chlorine (26) resulted
in a ∼3-fold increase in aﬃnity and potency.
Substitution of i-Pr at the R3 position by a c-Pr induced an
increase in aﬃnity and potency in all cases (27−29). As observed
in Table 3, replacing F at R2 in 27 by Cl in 30 led to an increased
aﬃnity and potency and a concomitant increase in kon. The data
in Table 4 show that kon values followed aﬃnity, whereas RT
values were all within a narrow range (8.2−11.9 min).
In addition to the results obtained with the ﬁrst subseries of
triazolopyridines 8−23, a 4-methoxy-3-pyridine moiety con-
nected by a methylene spacer was introduced, leading to
compounds 31−35 (Table 5). Thesemolecules share amoderate
to good potency and aﬃnity (pEC50 = 6.8−7.8; pKi = 7.9−8.7).
Removal of the ﬂuorine at the R2 position (32) did not
signiﬁcantly change aﬃnity, potency, or kinetic parameters when
compared to 31. Changing the ether linker in 31 and 32 to an
amine in 33 and 34 resulted in an approximately 3-fold increase
in aﬃnity and potency. A moderate increase in kon was observed
Table 4. Functional Activity (pEC50), Aﬃnity (pKi), and Kinetic Parameters (kon, koff, RT) for mGlu2 PAMs 24−30
compd R1 R2 R3 pEC50
a pKi
b kon (M
−1 min−1)b koff (min
−1)b RT (min)b,c KD (nM)
b,d
24 Cl F i-Pr 6.65 (6.43; 6.88) 7.21 ± 0.07 (5.0 ± 1.2) × 106 0.101 ± 0.009 9.9 ± 0.9 20.3 ± 5.4
25 CF3 F i-Pr 7.03 (7.44; 6.62) 8.05 ± 0.10 (4.6 ± 1.1) × 10
7 0.100 ± 0.029 10.0 ± 2.9 2.2 ± 0.8
26 CF3 Cl i-Pr 7.76 (7.55; 7.96) 8.41 ± 0.07 (3.6 ± 1.3) × 10
7 0.121 ± 0.035 8.2 ± 2.4 3.4 ± 1.6
27 Cl F c-Pr 7.20 (7.19; 7.21) 7.99 ± 0.05 (4.8 ± 1.5) × 106 0.061 ± 0.006 16.4 ± 1.7 12.7 ± 4.1
28 CF3 F c-Pr 7.52 (7.60; 7.43) 8.44 ± 0.07 (7.7 ± 4.8) × 10
7 0.086 ± 0.018 11.9 ± 2.3 1.1 ± 0.7
29 CF3 Cl c-Pr 8.11 (8.04; 8.18) 8.65 ± 0.11 (7.7 ± 3.8) × 10
7 0.088 ± 0.007 11.3 ± 0.9 1.2 ± 0.6
30 Cl Cl c-Pr 7.53 (7.54; 7.51) 8.17 ± 0.03 (1.4 ± 0.35) × 107 0.084 ± 0.016 11.9 ± 2.3 6.1 ± 1.9
aValues represent the mean followed by individual values in parentheses. bValues represent the mean ± SEM of at least three individual experiments.
cRT = 1/koff.
dKinetic KD values, deﬁned as KD = koff /kon.
Table 5. Functional Activity (pEC50), Aﬃnity (pKi), and Kinetic Parameters (kon, koff, RT) for mGlu2 PAMs 31−35
compd R1 R2 X pEC50
a pKi
b kon (M
−1 min−1)b koff (min
−1)b RT (min)b,c KD (nM)
b,d
31 CF3 F O 7.39 (7.40; 7.37) 7.93 ± 0.14 (1.1 ± 0.40) × 10
7 0.173 ± 0.007 5.8 ± 0.2 16.0 ± 5.9
32 CF3 H O 7.24 ± 0.07 8.06 ± 0.16 (1.4 ± 0.86) × 10
7 0.125 ± 0.013 8.0 ± 0.8 8.7 ± 5.4
33 CF3 F NH 8.23 (8.13; 8.33) 8.69 ± 0.16 (1.5 ± 0.94) × 10
7 0.044 ± 0.005 22.7 ± 2.8 2.9 ± 1.9
34 CF3 H NH 7.82 ± 0.05 8.50 ± 0.09 (3.4 ± 1.3) × 10
7 0.069 ± 0.012 14.6 ± 2.6 2.0 ± 0.8
35 Cl H NH 6.82 (6.94; 6.71) 8.13 ± 0.08 (6.2 ± 1.6) × 106 0.097 ± 0.022 10.3 ± 2.3 15.6 ± 5.3
aValues represent the mean followed by individual values in parentheses when of two experiments and the mean ± SEM when of three or more
experiments. bValues represent the mean ± SEM of at least three individual experiments, all performed in duplicate. cRT = 1/koff.
dKinetic KD values,
deﬁned as KD = koff/kon.
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and interestingly a 4- and 2-fold increase in RT for 33 and 34,
respectively. This may be explained by the increased ﬂexibility
given by the methylene bridge between the triazolopyridine core
and the pyridine substituent. As seen in many examples,
substitution of CF3 in 34 to Cl in 35 led to a decrease in aﬃnity,
potency, and kinetic parameter values.
Reducing aromaticity and introducing more aliphatic and sp3
character can sometimes be beneﬁcial for physicochemical
properties and druglikeness.44 In order to evaluate the eﬀects of
aromaticity, the 4-methoxy-3-pyridyl substituent was replaced
with a 4-tetrahydropyranyl ring (36, Table 6). This change
resulted in a pKi and potency (pEC50) of 6.65 and 7.64,
respectively, which were increased in 37 by the introduction of
CF3 in the R
1 position. Compound 37 has a high aﬃnity (pKi =
8.28) and increased kon (2.0 × 10
7 M−1 min−1); however,
contrary to the high aﬃnity, its RT (4.1 min) was the shortest
found throughout this study. As seen in the ﬁrst series of ligands
(Table 2), aﬃnity and potency did not change by altering the
linker atom from ether to amine (38, 39). Increasing the linker
length by a single methylene unit resulted in an approximately
10-fold loss in aﬃnity, (40; pKi = 7.21). Values for kon followed
aﬃnity, but RT values were all in the same range.
The tetrahydropyran moiety was then replaced by a
cyclohexanol ring, leading to 41−48. Again, compounds bearing
CF3 at R
1 (42, 46) showed better aﬃnity and potency than their
chlorine analogues (41, 45). Molecule 42 showed not only a high
potency (pEC50 = 8.03), aﬃnity (pKi = 8.66), and kon (1.1 × 10
7
M−1min−1) but also a longer RT of 31 min. Its cis-diastereomer
43 showed a 3-fold reduction in potency (pEC50 = 7.38) and
aﬃnity (pKi = 8.03), a 2-fold reduction in kon (5.7 × 10
6 M−1
min−1), and a small reduction in RT (17 min). Introduction of a
c-Pr substituent at R3 (44) led to an increase in potency (pEC50 =
8.95), aﬃnity (pKi = 9.05), and kon (1.4 × 10
7 M−1min−1) and
also to a prolonged RT of 50 min, which was the highest value
observed in this study. It may be that the cyclopropyl at R3 directs
the hydrophilic hydroxyl into a better position for interaction
with the receptor. Changing R4 from c-Pr to CF3 (45) did not
change any parameter compared to 41. Changing the linker
group from amine in 43 to ether in 46 did not aﬀect aﬃnity and
potency. However, RT seemed to be somewhat increased.
Diﬀerences between diastereomers were seen again in 47 and 48.
Whereas the potencies were similar, aﬃnity was decreased 3-fold
and kon remained similar, while RT was prolonged by 2-fold
when moving from a trans to cis conﬁguration.
In general, CF3 was shown to be the preferred substituent at
R1. Compounds bearing this substituent typically had a higher
potency and aﬃnity. Interestingly, all PAMs with a RT longer
than 20 min bear this moiety, including 44 with the longest RT
seen in this study (50 min). On the other hand, molecule 37 had
the shortest RT (4.1 min) and also contains the CF3 group,
indicating that CF3 in itself is not the driver for long RT. At the R
2
position chlorine was shown to be the best substituent for high
potency and aﬃnity. PAMs bearing a substituted pyridine
revealed the importance of its substitutions in combination with
the position of the nitrogen in the ring for potency, aﬃnity, and
kinetic parameters.
The rather small diﬀerences in RT induced by substitutions at
the R1 and R2 positions at the central triazolopyridine core
indicated that this region does not induce large diﬀerences in RT.
On the other hand, small diﬀerences in the distal tail of the
compounds induced large diﬀerences in RT. As we have shown
previously, this triazolopyridine series binds with the scaﬀold and
R4 substituent in the deepest part of the receptor, while the distal
tail points to the extracellular side.39 These diﬀerences in RTmay
be explained by the tight receptor−ligand interactions of the
triazolopyridine core compared to looser interactions on the
extracellular side. Certain molecules may trap the more ﬂexible
ECL2 (or the tops of TMs 3 and 5) in conformations leading to
longer RT. Such induced ﬁt modulation of RT can involve
ordering of loops to partially block the binding pocket and
prevent ligand escape. This mechanism has been seen for
multiple targets from diﬀerent classes, among which the 5-HT2B
receptor as reported in the recently published LSD-bound crystal
structure.24,45 Selectivity of this series of mGlu2 PAMs for other
members of the mGlu family was good. Representatives (12, 27,
37, and 45) showed no activity at mGlu1, -3, -4, -5, -6, -7, or -8;
see Supporting Information Table S1.
In order to compare the kinetic parameters and aﬃnity, a
kinetic map was generated (Figure 2). In this map kon (x-axis), koff
(y-axis), and KD (diagonal lines) were plotted. Whereas koff
values were all within a small range of about 1 order of magnitude
between 0.020 min−1 (44) and 0.241 min−1 (37), kon values were
more diverse and were spread over almost 2 orders of magnitude
between 1.7 × 106 M−1 min−1 (40) to 7.7 × 107 M−1 min−1 (28
and 29). The molecules were plotted per subgroup, as presented
in the diﬀerent tables. This revealed that 8−23 and 24−30 were
mostly diverse in on-rates (8−23, (0.17−6.2) × 107 M−1 min−1;
24−30, (0.48−7.7) × 107 M−1 min−1), whereas 31−35 and 36−
48 were more diverse in oﬀ-rates (31−35, 0.044−0.17 min−1;
36−48, 0.020−0.24 min−1), indicating that an increased aﬃnity
between close analogues may be achieved by optimizing one
kinetic parameter at a time. Interestingly, the ﬁve reference
mGlu2 PAMs 2−5 and 7, which are very diverse in structure and
aﬃnity, diﬀered mostly in terms of on-rate ((0.21−4.6) × 106
M−1min−1), whereas oﬀ-rates were very close (0.086−0.13
min−1). As expected, the compounds with the highest aﬃnity
either have a long RT (44) or a fast kon (28, 29). Ideally, these
optimized parameters may be combined leading to an mGlu2
PAM with even more increased aﬃnity, which would be
represented in the top right corner of the kinetic map. For
further comparison, the compounds were arbitrarily divided into
short RT (RT < 10 min), medium RT (10−20 min,) and long
RT (>20 min) (Figure 2).
To gain more insight into the relationships between the
diﬀerent parameters studied, correlation plots weremade (Figure
3). First, the aﬃnity (pKi) and potency (pEC50) were shown to
be linearly correlated (Figure 3A). Second, the aﬃnity obtained
from the classical radioligand displacement assay (pKi) and
Figure 2. Kinetic map of all tested compounds. The dissociation rate
(pkoff; koff, min
−1) is plotted on the y-axis; the association rate (log kon;
kon, M
−1 min−1) is on the x-axis. Identical aﬃnity (pKD) values may
result from a diﬀerent combination of kon and koff (KD = koff/kon, diagonal
blue lines). Horizontal lines indicating a RT of 10 and 20 min divide the
compounds into short, medium, and long RT.
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aﬃnity obtained from kinetic parameters (pKD) were shown to
be correlated (Figure 3B). This further supported the use of the
kinetic SPA radioligand binding assay. Long RT PAMs were
shown to share a high aﬃnity and potency, but by itself a high
potency or aﬃnity does not predict a long RT (Figure 3A, Figure
3B, Figure S1). Then, the dissociation rate constants (pkoff) were
plotted against the kinetic aﬃnity data (pKD) (Figure 3C), which
did not show correlation. Interestingly, the association rate
constants (log kon) were strongly correlated to aﬃnity (pKD)
(Figure 3D). These parameters were both within a similar range
of roughly 2 orders of magnitude for the compounds of our
series. Interestingly, although having diﬀerent structures and in
some cases lower aﬃnities and kon values, the reference mGlu2
PAMs (2−5) also ﬁtted well in this correlation (Figure 3D). This
indicated that this correlation has likely revealed a general trend
for PAMs and how they bind at the mGlu2 receptor.
Correlations between kinetic parameters and aﬃnity have
been made before. Most of these studies found a correlation
between koff values and aﬃnity or eﬃcacy, for instance, on theM3
and A2A receptors.
46−48 However, a correlation between
association rate constants and aﬃnity, as was shown here for
mGlu2 PAMs, has also been observed before. Exemplary GPCRs
are the OX2 receptor and β2-adrenoreceptors
49,50 and other
targets such as the hERG channel.51,52 These correlations are
receptor-speciﬁc and may therefore be caused by diﬀerences in
receptor structure, dynamics, or local environment of the
receptor.
Recent simulation studies have stipulated the importance of
fast association rates for receptor occupancy and drug
dosing.33,53 One of the mechanisms that may be responsible
for these eﬀects is receptor rebinding, which is described as the
binding of freshly dissociated ligands from the local environment
of the receptor.54 These high local concentrations may lead to a
prolonged activity of the drug, even when concentrations within
the eﬀect compartment have fallen below therapeutic levels.55
For the mGlu2 receptor, rebinding may play a role. The
physiological synaptic environment of the receptor may permit
more rebinding as its interstitial location will result in less
diﬀusion and therefore higher local ligand concentrations.56,57
Another reason for receptor rebinding would be binding of
compound to or in the cell membrane close to the receptor which
may then act as a repository and facilitate the approach of the
compound to the receptor.56 This would, however, require a
correlation between lipophilicity and association rate constants,
as lipophilic compounds are more likely to bind to the cell
membrane. Since the plot in Figure 3E shows no such correlation
for the studied mGlu2 PAMs, membrane binding is not likely to
be involved for these compounds.
xCELLigence. We used a label-free, impedance-based
technology (xCELLigence) to evaluate whether a long receptor
binding RT leads to a prolonged functional activity. This method
is based on the measurement of cellular impedance, expressed as
cell index, and enables real-time recordings.58 Responses induced
by compound addition can thus be measured and quantiﬁed.
Earlier studies have shown that results obtained were comparable
to more classical end point assays.59 As the assay is performed on
whole cells at 37 °C, it is considered a valuable translational step
toward in vivo experiments.60 Endogenous glutamate levels at
the time of experiments were around 90 μM. Compound-
induced responses therefore represent the PAM eﬀects. As a
control, reference compound 7 was used to check the response
on CHO-K1 WT cells compared to CHO-K1_hmGlu2 cells
(Figure S2). No response was found on the WT cells, indicating
that the responses were mGlu2 receptor-mediated. For further
experiments we selected compounds with diversity in RT
(measured at 28 °C): 37 (4.1 min), its close analogue 39 with 3-
to 4-fold longer RT (15 min), and 44 with again a 3-fold longer
RT compared to 39 (50 min; Figure 4A−D). We determined
their potency in the label-free assay using CHO-K1_hmGlu2
cells and found pEC50 values of 7.05± 0.04, 7.73± 0.23 and 7.95
± 0.12, respectively. Then we performed a wash-out assay in
order to evaluate diﬀerences in compound-induced responses
after washing. This enabled us to trace the remaining response
exerted by only receptor-bound compound. To this end we ﬁrst
determined the EC80 concentrations of short RT 37, medium RT
39, and long RT 44, which were 600, 200, and 60 nM,
Figure 3. Correlation between aﬃnity (pKi) and potency (pEC50) (A); aﬃnity determined from [
3H]-7 displacement assays (pKi) and aﬃnity
determined based on kinetic parameters kon and koff obtained from [
3H]-7 competition association experiments (pKD) (B); aﬃnity (pKD) and
dissociation rate (pkoff) (C); aﬃnity (pKD) and association rate (log kon) (D); association rate (log kon) and partition coeﬃcient (clogP) (E).
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respectively. Then, cells were stimulated with this EC80
concentration, and just before maximal response was reached,
after 5 min, cells were washed and fresh medium was added
(Figure 4E−G). By comparing these traces with control traces of
unwashed wells, we evaluated the diﬀerences in responses
between 37, 39, and 44 as the ratio between the AUC of washed
and unwashed wells (Figure 4H). The functional eﬀect of 37 and
39 was partially lost in this experimental setup, while the eﬀect of
44 remained almost unchanged. The wash-out assay showed a
signiﬁcant diﬀerence between short RT 37 and long RT 44. The
value for 39 was in between those of 37 and 44, in agreement
with its RT. Together, these data showed that a longer RT also
leads to an increased functional eﬀect under nonequilibrium
conditions and that these parameters are positively correlated.
Since equilibrium conditions are not always present in
physiological conditions, these ﬁndings may be considered a
translational step from in vitro toward in vivo experiments.
In Vivo Sleep−Wake Eﬀects.Glutamate neurotransmission
plays a key role in sleep−wake mechanisms, and these processes
have translational value for central activity and target engage-
ment. Previous in vivo studies have repeatedly shown that
positive allosteric modulation of the mGlu2 receptor results in
distinct changes in rodent sleep−wake organization, more
speciﬁcally in a dose-dependent reduction in so-called rapid
eye movement sleep or REM sleep.61,62 Changes in sleep−wake
states in the rat are of a dynamic nature, i.e., with more frequent
transitions between sleep−wake states as compared to humans:
therefore the eﬀects of mGlu2 PAM compounds on REM sleep
are expressed as averages over, for example, 2 or 4 h periods after
compound administration. In order to investigate whether the
diﬀerent RT values are reﬂected in the sleep−wake related
pharmacodynamic readout, sleep−wake analysis of 9 and 20
(selected as examples with long versus short in vitro RT,
respectively, yet having appropriate and similar pharmacokinetic
behavior) was even done on a 5 min basis to optimally capture
sleep changes in function of time. All methods, (circadian)
timings, and analyses otherwise were similar to those reported
earlier by Ahnaou et al. (2016).62
Figure 5 shows the eﬀects of 9 and 20 on REM sleep reduction
in rats for 24 consecutive 5 min periods after a single oral
administration of 1, 3, and10mg/kg and 20%CD vehicle control.
The ﬁrst 6 consecutive 5 min periods can be discarded due to the
Figure 4. Concentration-dependent eﬀects of 37 (A), 39 (B), and 44 (C) on CHO-K1 cells stably expressing the human mGlu2 receptor. A
representative example is shown of a baseline-corrected response, which was repeated three times in duplicate. (D) Concentration−eﬀect curves of 37,
39, and 44, derived from the AUC up to 150 min. Data are from three individual experiments performed in duplicate and are expressed as percentage of
maximum AUC. Responses in a label-free, impedance-based assay induced by an EC80 equivalent concentration of 37 (600 nM) (E), 39 (200 nM) (F),
and 44 (60 nM) (G) with and without washing step induced 5min after stimulation. A representative example is shown of a baseline-corrected response,
which was repeated three times in duplicate. (H) Ligand-induced response that is left after washing step. Data are expressed as the ratio between the
AUC of the trace of the washed and unwashed wells. Data are from three individual experiments performed in duplicate and are expressed as the mean±
SEM: (∗) p < 0.05.
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confounding arousing eﬀect of the oral administration procedure
per se, the animal returning to undisturbed REM sleep baseline
values after about 30 min. Molecule 9 showed a longer in vitro
RT of 30 min, while for 20 it was 5 min. Correspondingly, at the
higher dose of 10 mg/kg, the eﬀect of 9 on REM reduction
seemed more immediate and constant compared to 20. For both
compounds no eﬀects on total sleep were seen (Figure S3).
Compounds 9 and 20 showed similar in vitro binding aﬃnities
with pKi values of 8.59 and 8.44, respectively. At 10 mg/kg,
estimated free levels in brain 1 h after administration are 5 and 3.5
ng/g for 9 and 20, respectively. Hence the two molecules show
similar aﬃnity and roughly similar range of free concentrations in
brain. While the underlying mechanism causing this diﬀerent in
vivo eﬀect is still to be elucidated, this ﬁnding provides a ﬁrst hint
that diﬀerent RTs may impact the in vivo eﬀect. The interplay of
RT with elimination/clearance from brain is important for the
resulting in vivo eﬀect, but with similar levels of 9 and 20 after 1 h,
it seems that RT may play a role in this case. To strengthen these
observations, future experiments could include the synthesis of
PET ligands with diﬀerent residence times and further in vivo
studies with a diﬀerent end point such as cognition.
While potent GPCR antagonists can act via a long RT with
expected improved clinical eﬃcacy, there is limited published
data assessing the relationship between agonist/PAM RT and in
vivo eﬃcacy. Agonist responses are usually regulated by receptor
desensitization and internalization, which can act to limit the
eﬀect and duration of receptor signaling. PAMs do not activate
receptors in the absence of agonist, and hence allosteric
modulators with prolonged action may not be negated by
internalization and loss of function due to longer RT of the
PAM−receptor complex.
■ CONCLUSIONS
In this study we described a series of 7-aryl-1,2,4-triazolo[4,3-
a]pyridines with potent mGlu2 PAM activity and a high aﬃnity.
An SPA radioligand binding assay was developed to study the
kinetic parameters of these compounds. We showed that
association rate constants range within 3 orders of magnitude,
whereas RT values are more conﬁned, from 4.1 min (37) up to
50 min (44). Correlation plots between aﬃnity and kinetic
parameters revealed a strong correlation between aﬃnity and
association rate constants, whereas no such correlation was
found between RT and aﬃnity.
Structure−kinetics relationships were explored in addition to
the more traditional structure−activity/aﬃnity relationships
analysis. We learned that a CF3 substituent at R
1 increased
potency and aﬃnity and was also important for RT but did not
lead to a long RT per se as shown by its presence in 37 (“short”
RT) and 44 (“long” RT). Chlorine was the preferred substituent
for R2, it increased potency and aﬃnity but not RT. Diﬀerences in
the distal tail of the molecules, such as small changes in the
pyridine moiety or single substitutions to the cyclohexanol,
induced the biggest diﬀerences in RT. This was exempliﬁed by
the introduction of c-Pr in 44, leading to a 3-fold increase in RT
compared to 43.
To evaluate whether a long RT also leads to a prolonged
functional eﬀect, 37, 39, and 44 were evaluated in a wash-out
assay using the label-free impedance based xCELLigence
technique. The response of 44 on whole cells at physiological
temperature remained more sustained after washing than that of
37 and 39. These data suggested that an increased lifetime of the
receptor−ligand complex (RT) is correlated to an increased
functional eﬀect under nonequilibrium conditions.
Together, these results show for the ﬁrst time for a class C
GPCR that optimization of ligand binding kinetics in addition to
Figure 5. Average amount of REM sleep in minutes for 24 consecutive 5 min period during the ﬁrst 2 h of the recording session after oral administration
of 9 (top panel) and 20 (bottom panel), each at 1, 3, 10mg/kg, po, to Sprague-Dawley rats (n = 8 for each condition). Black lines indicate control vehicle
condition (20% CD), while the green, blue, and red lines indicate doses of 1, 3, 10 mg/kg, respectively. Error ﬂags indicate SEM values: note that the
higher time resolution of 5 min bins also causes REM sleep changes to be expressed more dynamically and less “consistent” as compared to reduction
score averaged over the whole 2 h postadministration period. ∗ indicates p < 0.05 vehicle compared to 10 mg/kg, mixed model ANOVA.
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potency and aﬃnity is possible. Given that pure PAMs do not
exert an eﬀect in the absence of glutamate and are thus less likely
to induce on-target toxicity, a long RT seems a promising
strategy for these ligands. As rebinding may be involved in mGlu2
receptor occupancy, a RT for 44 in our system of 50 min may be
prolonged in the interstitial synaptic environment. Without any
on-target toxicity occurring, the design of mGlu2 PAMs with
even longer RTs may be a logical next step. Lastly, a ﬁrst attempt
was made to relate the compound’s RT to its in vivo
pharmacodynamic eﬀect. Ultimately, this study may contribute
to the development of compounds with a high aﬃnity and
eﬃcacy in vitro and in vivo, not only for the mGlu2 receptor but
also for other GPCRs.
■ EXPERIMENTAL SECTION
Chemistry. Unless otherwise noted, all reagents and solvents were
obtained from commercial suppliers and used without further
puriﬁcation. Thin layer chromatography (TLC) was carried out on
silica gel 60 F254 plates (Merck). Flash column chromatography was
performed on silica gel, particle size 60 Å, mesh of 230−400 (Merck)
under standard techniques. Microwave assisted reactions were
performed in a single-mode reactor, Biotage Initiator Sixty microwave
reactor (Biotage), or in a multimode reactor, MicroSYNTH Labstation
(Milestone, Inc.). Nuclear magnetic resonance (NMR) spectra were
recorded with either a Bruker DPX-400 or a Bruker AV-500
spectrometer (Bruker AG) with standard pulse sequences, operating
at 400 and 500 MHz, respectively, using CDCl3 and DMSO-d6 as
solvents. Chemical shifts (δ) are reported in parts per million (ppm)
downﬁeld from tetramethylsilane (δ = 0). Coupling constants are
reported in hertz. Splitting patterns are deﬁned by s (singlet), d
(doublet), dd (double doublet), t (triplet), q (quartet), quin (quintet),
sex (sextet), sep (septet), or m (multiplet). Liquid chromatography
combined with mass spectrometry (LC−MS) was performed on either a
HP 1100 HPLC system (Agilent Technologies) or Advanced
Chromatography Technologies system composed of a quaternary or
binary pump with degasser, an autosampler, a column oven, a diode
array detector (DAD), and a column as speciﬁed in the respective
methods below. Flow from the column was split to a MS spectrometer.
The MS detector was conﬁgured with either an electrospray ionization
source or an ESCI dual ionization source (electrospray combined with
atmospheric pressure chemical ionization). Nitrogen was used as the
nebulizer gas. Data acquisition was performed withMassLynx-Openlynx
software or with Chemsation-Agilent data browser software. Melting
point values are peak values and were obtained with experimental
uncertainties that are commonly associated with this analytical method.
Melting points were determined in open capillary tubes on a Mettler
FP62 apparatus with a temperature gradient of 10 °C/min. Maximum
temperature was 300 °C.
Purities of all new compounds were determined by analytical RP
HPLC using the area percentage method on the UV trace recorded at a
wavelength of 254 nm, and compounds were found to have≥95% purity
unless otherwise speciﬁed.
8-Chloro-3-cyclopropylmethyl-7-{4-[(2,6-dimethylpyridin-3-
yl)oxy]-3-ﬂuorophenyl}[1,2,4]triazolo[4,3-a]pyridine (8). To a
stirred suspension of 50a (1.7 g, 5.09 mmol) and 52a (2.1 g, 6.12 mmol)
in a saturated aqueous solution of NaHCO3 (18 mL) and 1,4-dioxane
(36 mL) was added Pd(PPh3)4 (0.589 g, 0.51 mmol). The mixture was
heated at 150 °C for 10 min under microwave irradiation. The mixture
was cooled to room temperature and ﬁltered through a Celite pad. The
ﬁltrate was diluted with water (20 mL) and extracted with EtOAc (2 ×
15 mL). The organic layer was washed with brine (15 mL), dried over
anhydrous Na2SO4, and concentrated in vacuo. The crude was puriﬁed
by ﬂash column chromatography (silica gel, EtOAc in DCM, 0/100 to
20/80) to give the desired product 8 as a white solid (1.3 g, 60%). Mp
207.2 °C. 1H NMR (500 MHz, CDCl3) δ ppm 0.32−0.42 (m, 2H),
0.61−0.69 (m, 2H), 1.17−1.28 (m, 1H), 2.54 (s, 3H), 2.55 (s, 3H), 3.13
(d, J = 6.9 Hz, 2H), 6.87 (d, J = 6.9Hz, 1H), 6.92 (t, J = 8.4 Hz, 1H), 7.02
(d, J = 8.4 Hz, 1H), 7.16 (d, J = 8.4 Hz, 1H), 7.25 (d, J = 9.2 Hz, 1H),
7.41 (dd, J = 11.3, 1.7 Hz, 1H), 7.98 (d, J = 6.9 Hz, 1H). LC−MS m/z
423 [M + H]+, tR = 2.86 min.
8-Triﬂuoromethyl-3-cyclopropylmethyl-7-{4-[(2,6-dimethyl-
pyridin-3-yl)oxy]-3-ﬂuorophenyl}[1,2,4]triazolo[4,3-a]pyridine
(9). Starting from 49a (0.150 g, 0.54 mmol) and 52a (0.242 g, 0.707
mmol) and following the procedure described for 8, compound 9 was
obtained as a white solid (0.139 g, 56%). 1HNMR (400MHz, CDCl3) δ
ppm 0.31−0.43 (m, 2H), 0.61−0.70 (m, 2H), 1.16−1.30 (m, 1H), 2.53
(s, 3H), 2.55 (s, 3H), 3.15 (d, J = 6.7 Hz, 2H), 6.79 (d, J = 7.2 Hz, 1H),
6.89 (t, J = 8.3 Hz, 1H), 7.01 (d, J = 8.3 Hz, 1H), 7.05 (br d, J = 8.6 Hz,
1H), 7.14 (d, J = 8.3 Hz, 1H), 7.22 (dd, J = 10.9, 2.1 Hz, 1H), 8.11 (d, J =
7.2 Hz, 1H). LC−MS m/z 457 [M + H]+, tR = 3.03 min.
8-Methyl-3-cyclopropylmethyl-7-{4-[(2,6-dimethylpyridin-3-
yl)oxy]-3-ﬂuorophenyl}[1,2,4]triazolo[4,3-a]pyridine (10). Start-
ing from 51a (0.250 g, 1.127 mmol) and 52a (0.464 g, 1.35 mmol) and
following the procedure described for 8, compound 10was obtained as a
white solid (0.103 g, 23%). Mp 147.4 °C. 1H NMR (500 MHz, CDCl3)
δ ppm 0.32−0.39 (m, 2H), 0.60−0.67 (m, 2H), 1.16−1.29 (m, 1H),
2.55 (s, 6H), 2.65 (s, 3H) 3.11 (d, J = 6.65 Hz, 2H), 6.78 (d, J = 7.22 Hz,
1H), 6.93 (t, J = 8.38 Hz, 1H), 7.00 (d, J = 8.38 Hz, 1H), 7.07 (d, J = 8.38
Hz, 1H), 7.13 (d, J = 8.09 Hz, 1H), 7.23 (dd, J = 11.27, 2.02 Hz, 1H),
7.89 (d, J = 6.94 Hz, 1H). LC−MS m/z 403 [M + H]+, tR = 2.07 min.
8-Cyclopropyl-3-cyclopropylmethyl-7-{4-[(2,6-dimethylpyri-
din-3-yl)oxy]-3-ﬂuorophenyl}[1,2,4]triazolo[4,3-a]pyridine
(11). Starting from 51b (0.230 g, 0.93 mmol) and 52a (0.382 g, 1.11
mmol) and following the procedure described for 8, compound 11 was
obtained as a white solid (0.269 g, 68%). Mp 166.4 °C. 1H NMR (400
MHz, CDCl3) δ ppm 0.29−0.38 (m, 2H), 0.58−0.67 (m, 2H), 0.90−
1.00 (m, 2H), 1.14−1.31 (m, 1H), 1.55−1.70 (m, 2H) 2.10 (tt, J = 8.64,
5.46 Hz, 1H), 2.54 (s, 3H), 2.55 (s, 3H), 3.06 (d, J = 6.70 Hz, 2H), 6.73
(d, J = 7.17 Hz, 1H), 6.93 (t, J = 8.44 Hz, 1H), 7.00 (d, J = 8.32 Hz, 1H),
7.13 (d, J = 8.32 Hz, 1H), 7.15−7.20 (m, 1H), 7.32 (dd, J = 11.21, 1.97
Hz, 1H), 7.80 (d, J = 7.17Hz, 1H). LC−MSm/z 429 [M+H]+, tR = 2.24
min.
8-Chloro-3-cyclopropylmethyl-7-{4-[(2,6-dimethylpyridin-3-
yl)oxy]-3-chlorophenyl}[1,2,4]triazolo[4,3-a]pyridine (12). Start-
ing from 50a (0.250 g, 0.75 mmol) and 52b (0.385 g, 0.75 mmol) and
following the procedure described for 8, compound 12was obtained as a
white solid (0.100 g, 70%). Mp 182.7 °C. 1H NMR (400 MHz, CDCl3)
δ ppm 0.31−0.41 (m, 2H), 0.57−0.70 (m, 2H), 1.21−1.33 (m, 1H),
2.51 (s, 3H), 2.56 (s, 3H), 3.13 (d, J = 6.94 Hz, 2H), 6.82 (d, J = 8.55 Hz,
1H), 6.87 (d, J = 6.94Hz, 1H), 7.03 (d, J = 8.32Hz, 1H), 7.16 (d, J = 8.09
Hz, 1H), 7.37 (dd, J = 8.55, 2.31 Hz, 1H), 7.66 (d, J = 2.31 Hz, 1H), 7.97
(d, J = 7.17 Hz, 1H). LC−MS m/z 439 [M + H]+, tR = 3.08 min.
8-Triﬂuoromethyl-3-cyclopropylmethyl-7-{4-[(2,6-dimethyl-
pyridin-3-yl)oxy]-3-chlorophenyl}[1,2,4]triazolo[4,3-a]pyridine
(13). Starting from 49a (0.2 g, 0.73 mmol) and 52b (0.26 g, 0.72 mmol)
and following the procedure described for 8, compound 13was obtained
as a white solid (0.217 g, 61%). Mp > 300 °C. 1H NMR (400 MHz,
CDCl3) δ ppm 0.34−0.41 (m, 2H), 0.62−0.70 (m, 2H), 1.16−1.30 (m,
1H), 2.50 (s, 3H), 2.56 (s, 3H), 3.15 (d, J = 6.70 Hz, 2H), 6.79 (d, J =
8.09 Hz, 2H), 7.03 (d, J = 8.09 Hz, 1H), 7.11−7.19 (m, 2H), 7.49 (d, J =
2.31Hz, 1H), 8.10 (d, J = 7.17Hz, 1H). LC−MSm/z 473 [M+H]+, tR =
3.22 min.
8-Methyl-3-cyclopropylmethyl-7-{4-[(2,6-dimethylpyridin-3-
yl)oxy]-3-chlorophenyl}[1,2,4]triazolo[4,3-a]pyridine (14). Start-
ing from 60a (0.250 g, 0.127 mmol) and 52b (0.464 g, 1.35 mmol) and
following the procedure described for 8, compound 14was obtained as a
white solid (0.107 g, 22%). Mp 121 °C. 1H NMR (500 MHz, CDCl3) δ
ppm 0.36 (q, J = 5.01 Hz, 2H), 0.58−0.67 (m, 2H), 1.17−1.30 (m, 1H),
2.52 (s, 3H), 2.56 (s, 3H), 2.64 (s, 3H), 3.11 (d, J = 6.65 Hz, 2H), 6.78
(d, J = 6.94 Hz, 1H), 6.83 (d, J = 8.67 Hz, 1H), 7.02 (d, J = 8.38 Hz, 1H),
7.13 (d, J = 8.09 Hz, 1H), 7.18 (dd, J = 8.38, 2.02 Hz, 1H), 7.49 (d, J =
2.31Hz, 1H), 7.89 (d, J = 6.94Hz, 1H). LC−MSm/z 419 [M+H]+, tR =
2.23 min.
8-Chloro-3-cyclopropylmethyl-7-{4-[(2-methylpyridin-4-yl)-
oxy]-3-ﬂuororophenyl}[1,2,4]triazolo[4,3-a]pyridine (15). Start-
ing from 50a (1.71 g, 5.13 mmol) and 52c (1.4 g, 5.67 mmol) and
following the procedure described for 8, compound 15was obtained as a
white solid (0.100 g, 70%). Mp > 300 °C. 1H NMR (500 MHz, CDCl3)
δ ppm 0.34−0.41 (m, 2H), 0.63−0.70 (m, 2H), 1.18−1.28 (m, 1H),
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2.55 (s, 3H), 3.14 (d, J = 6.65 Hz, 2H), 6.73 (dd, J = 5.78, 2.31 Hz, 1H),
6.78 (d, J = 2.31 Hz, 1H), 6.91 (d, J = 7.22 Hz, 1H), 7.27−7.34 (m, 1H),
7.36−7.41 (m, 1H), 7.45 (dd, J = 10.69, 2.02 Hz, 1H), 8.01 (d, J = 6.94
Hz, 1H), 8.41 (d, J = 5.78Hz, 1H). LC−MSm/z 409 [M+H]+, tR = 2.57
min.
8-Triﬂuoromethyl-3-cyclopropylmethyl-7-{4-[(2-methylpyri-
din-4-yl)oxy]-3-ﬂuororophenyl}[1,2,4]triazolo[4,3-a]pyridine
(16). Starting from 49a (1.4 g, 5.08 mmol) and 52c (1.84 g, 5.59 mmol)
and following the procedure described for 8, compound 16was obtained
as a white solid (0.233 g, 10%). Mp 194.6 °C. 1H NMR (500 MHz,
CDCl3) δ ppm 0.34−0.44 (m, 2 H), 0.61−0.73 (m, 2H), 1.18−1.29 (m,
1H), 2.55 (s, 3H), 3.17 (d, J = 6.66 Hz, 2H), 6.70 (dd, J = 5.8, 2.6 Hz,
1H), 6.76 (d, J = 2.3 Hz, 1H), 6.83 (d, J = 7.2 Hz, 1H), 8.20 (br d, J = 8.4
Hz, 1H), 7.23−7.31 (m, 2H), 8.14 (d, J = 7.2 Hz, 1H), 8.41 (d, J = 5.8
Hz, 1H). LC−MS m/z 443 [M + H]+, tR = 2.70 min.
8-Chloro-3-cyclopropylmethyl-7-{4-[(2-ethylpyridin-4-yl)-
oxy]-3-ﬂuororophenyl}[1,2,4]triazolo[4,3-a]pyridine (17). Start-
ing from 50a (0.26 g, 0.78 mmol) and 52d (0.293 g, 0.857 mmol) and
following the procedure described for 8, compound 17was obtained as a
white solid (0.316 g, 96%). Mp > 300 °C. 1H NMR (500 MHz, CDCl3)
δ ppm 0.31−0.43 (m, 2H), 0.60−0.72 (m, 2H), 1.15−1.29 (m, 1H),
1.31 (t, J = 7.7 Hz, 3H), 2.82 (q, J = 7.6 Hz, 2H), 3.14 (d, J = 6.6 Hz, 2H),
6.72 (dd, J = 5.8, 2.3 Hz, 1H), 6.81 (d, J = 2.3 Hz, 1H), 6.91 (d, J = 6.9
Hz, 1H), 7.31 (t, J = 8.2 Hz, 1H), 7.35−7.42 (m, 1H), 7.45 (dd, J = 10.7,
2.0 Hz, 1H), 8.01 (d, J = 6.9 Hz, 1H), 8.44 (d, J = 5.8 Hz, 1H). LC−MS
m/z 423 [M + H]+, tR = 2.04 min.
8-Triﬂuoromethyl-3-cyclopropylmethyl-7-{4-[(2,6-dimethyl-
pyridin-4-yl)oxy]-3-ﬂuororophenyl}[1,2,4]triazolo[4,3-a]-
pyridine (18). Starting from 49a (0.185 g, 0.67 mmol) and 52e (0.3 g,
0.874mmol) and following the procedure described for 8, compound 18
was obtained as a white solid (0.100 g, 33%). Mp 232.5 °C. 1H NMR
(500 MHz, CDCl3) δ ppm 0.24−0.50 (m, 2H), 0.55−0.79 (m, 2H),
1.05−1.39 (m, 1H), 2.50 (s, 6H), 3.17 (d, J = 6.70 Hz, 2H), 6.56 (s, 2H),
6.84 (d, J = 7.17 Hz, 1H), 7.16−7.21 (m, 1H), 7.22−7.29 (m, 2H), 8.14
(d, J = 7.17 Hz, 1 H). LC−MS m/z 457 [M + H]+, tR = 2.94 min.
8-Chloro-3-cyclopropylmethyl-7-{4-[(2-cyclopropylpyridin-
4-yl)oxy]-3-ﬂuororophenyl}[1,2,4]triazolo[4,3-a]pyridine (19).
Starting from 50a (0.103 g, 0.310 mmol) and 52f (0.22 g, 0.310
mmol) and following the procedure described for 8, compound 19 was
obtained as a white solid (0.06 g, 45%). Mp > 300 °C. 1H NMR (500
MHz, CDCl3) δ ppm 0.38 (q, J = 5.11 Hz, 2H), 0.62−0.71 (m, 2H),
0.95−1.09 (m, 4H), 1.16−1.29 (m, 1H), 1.94−2.03 (m, 1H), 3.14 (d, J =
6.65 Hz, 2H), 6.66 (dd, J = 5.64, 2.46 Hz, 1H), 6.78 (d, J = 2.31 Hz, 1H),
6.90 (d, J = 6.94 Hz, 1H), 7.28−7.33 (m, 1H), 7.34−7.40 (m, 1H), 7.44
(dd, J = 10.69, 2.02 Hz, 1H), 8.00 (d, J = 6.94 Hz, 1H), 8.35 (d, J = 5.78
Hz, 1H). LC−MS m/z 435 [M + H]+, tR = 4.51 min.
8-Triﬂuoromethyl-3-cyclopropylmethyl-7-{4-[(2-cyclopro-
pylpyridin-4-yl)oxy]-3-ﬂuororophenyl}[1,2,4]triazolo[4,3-a]-
pyridine (20). Starting from 49a (0.2 g, 0.725 mmol) and 52f (0.283 g,
0.798mmol) and following the procedure described for 8, compound 20
was obtained as a white solid (0.058 g, 17%). Mp 211.1 °C. 1H NMR
(500 MHz, CDCl3) δ ppm 0.32−0.45 (m, 2H), 0.53−0.75 (m, 2H),
0.96−1.03 (m, 2H), 1.02−1.08 (m, 2H), 1.16−1.30 (m, 1H), 1.91−2.03
(m, 1H), 3.16 (d, J = 6.7 Hz, 2H), 6.63 (dd, J = 5.8, 2.3 Hz, 1H), 6.75 (d,
J = 2.3 Hz, 1H), 6.83 (d, J = 7.2 Hz, 1H), 7.15−7.22 (m, 1H), 7.22−7.31
(m, 2H), 8.15 (d, J = 6.9 Hz, 1H), 8.35 (d, J = 5.5 Hz, 1H). LC−MSm/z
469 [M + H]+, tR = 3.31 min.
8-Chloro-3-(2,2,2-triﬂuoroethyl-7-{4-[(2,6-dimethylpyridin-
3-yl)oxy]-3-ﬂuorophenyl}[1,2,4]triazolo[4,3-a]pyridine (21).
Starting from 56c (0.2 g, 0.55 mmol) and 52a (0.228 g, 0.664 mmol)
and following the procedure described for 8, compound 21was obtained
as a white solid (0.032 g, 13%). Mp 164.5 °C. 1H NMR (500 MHz,
CDCl3) δ ppm 2.53 (s, 3H), 2.55 (s, 3H), 4.11 (q, J = 9.9 Hz, 2H), 6.93
(t, J = 8.3 Hz, 1H), 6.98 (d, J = 7.2 Hz, 1H), 7.02 (d, J = 8.3 Hz, 1H), 7.16
(d, J = 8.3 Hz, 1H), 7.23−7.28 (m, 1H), 7.42 (dd, J = 11.1, 2.1 Hz, 1H),
8.01 (d, J = 7.2 Hz, 1H). LC−MS m/z 451 [M + H]+, tR = 3.24 min.
8-Chloro-3-(ethoxymethyl-7-{4-[(2,6-dimethylpyridin-3-yl)-
oxy]-3-ﬂuorophenyl}[1,2,4]triazolo[4,3-a]pyridine (22). Starting
from 50b (0.4 g, 1.19 mmol) and 52a (0.488 g, 1.42 mmol) and
following the procedure described for 8, compound 22was obtained as a
white solid (0.310 g, 61%). Mp 180.3 °C. 1H NMR (500 MHz, CDCl3)
δ ppm 1.23 (t, J = 6.94 Hz, 3H), 2.54 (s, 3 H), 2.55 (s, 3H), 3.58 (q, J =
6.94 Hz, 2H), 5.10 (s, 2H), 6.87−6.95 (m, 2H), 7.02 (d, J = 8.09 Hz,
1H), 7.16 (d, J = 8.09 Hz, 1H), 7.22−7.26 (m, 1H), 7.42 (dd, J = 11.27,
2.31Hz, 1H), 8.25 (d, J = 7.22Hz, 1H). LC−MSm/z 427 [M+H]+, tR =
2.77 min.
8-Triﬂuoromethyl-3-(ethoxymethyl-7-{4-[(2,6-dimethylpyri-
din-3-yl)oxy]-3-ﬂuorophenyl}[1,2,4]triazolo[4,3-a]pyridine
(23). Starting from 49b (0.150 g, 0.536 mmol) and 52a (0.239 g, 0.697
mmol) and following the procedure described for 8, compound 23 was
obtained as a white solid (0.150 g, 61%). Mp 142.2 °C. 1H NMR (500
MHz, CDCl3) δ ppm 1.23 (t, J = 7.08 Hz, 3H), 2.53 (s, 3H), 2.54 (s,
3H), 3.59 (q, J = 7.13 Hz, 2H), 5.12 (s, 2H), 6.82 (d, J = 7.22 Hz, 1H),
6.90 (t, J = 8.24 Hz, 1H), 7.01 (d, J = 8.38 Hz, 1H), 7.06 (d, J = 8.09 Hz,
1H), 7.14 (d, J = 8.38Hz, 1H), 7.23 (dd, J = 10.69, 2.02 Hz, 1H), 8.40 (d,
J = 6.94 Hz, 1H). LC−MS m/z 461 [M + H]+, tR = 2.89 min.
8 - C h l o r o - 3 - c y c l o p r op y lme t h y l - 7 - [ 3 - ﬂuo r o - 4 -
(isopropylamino)phenyl][1,2,4]triazolo[4,3-a]pyridine (24).
Starting from 50a (0.350 g, 1.049 mmol) and 52g (0.381 g, 1.36
mmol) and following the procedure described for 8, compound 24 was
obtained as a white solid (0.097 g, 26%). Mp 196.4 °C. 1H NMR (500
MHz, CDCl3) δ ppm 0.35 (q, J = 5.20 Hz, 2H), 0.60−0.67 (m, 2H),
1.15−1.26 (m, 1H), 1.29 (d, J = 6.36 Hz, 6H), 3.10 (d, J = 6.65 Hz, H),
3.72 (dq, J = 13.19, 6.49Hz, 1H), 3.98 (br d, J = 5.20Hz, 1H), 6.70−6.81
(m, 1H), 6.87 (d, J = 6.94 Hz, 1H), 7.17−7.31 (m, 2H) 7.91 (d, J = 7.22
Hz, 1H). LC−MS m/z 359 [M + H]+, tR = 3.11 min.
8-Triﬂuoromethyl-3-cyclopropylmethyl-7-[3-ﬂuoro-4-
(isopropylamino)phenyl][1,2,4]triazolo[4,3-a]pyridine (25).
Starting from 49a (0.350 g, 1.27 mmol) and 52g (0.461 g, 1.65
mmol) and following the procedure described for 8, compound 25 was
obtained as a white solid (0.250 g, 50%). Mp 196.9 °C. 1H NMR (500
MHz, CDCl3) δ ppm 0.28−0.42 (m, 2H), 0.57−0.71 (m, 2H), 1.12−
1.26 (m, 1H), 1.29 (d, J = 6.4 Hz, 6H), 3.12 (d, J = 6.6 Hz, 2H), 3.64−
3.77 (m, 1H), 3.96 (d, J = 4.9 Hz, 1H), 6.74 (t, J = 8.4 Hz, 1H), 6.80 (d, J
= 7.2 Hz, 1H), 7.02 (d, J = 10.1 Hz, 2H), 8.04 (d, J = 6.9 Hz, 1H). LC−
MS m/z 393 [M + H]+, tR = 3.33 min.
8-Triﬂuoromethyl-3-cyclopropylmethyl-7-[3-chloro-4-
(isopropylamino)phenyl][1,2,4]triazolo[4,3-a]pyridine (26).
Starting from 49a (0.350 g, 1.27 mmol) and 52h (0.488 g, 1.65
mmol) and following the procedure described for 8, compound 26 was
obtained as a white solid (0.250 g, 50%). Mp 230 °C. 1H NMR (500
MHz, CDCl3) δ ppm 0.29−0.42 (m, 2H), 0.55−0.71 (m, 2H), 1.11−
1.27 (m, 1H), 1.31 (d, J = 6.36 Hz, 6H), 3.13 (d, J = 6.65 Hz, 2H), 3.73
(dq, J = 13.11, 6.51 Hz, 1H), 4.38 (br d, J = 7.51 Hz, 1H), 6.71 (d, J =
8.67 Hz, 1H), 6.79 (d, J = 7.22 Hz, 1H), 7.16 (dd, J = 8.38, 1.44 Hz, 1H),
7.30 (d, J = 2.02 Hz, 1H), 8.03 (d, J = 6.94 Hz, 1H). LC−MS m/z 409
[M + H]+, tR = 3.71 min.
8 - C h l o r o - 3 - c y c l o p r op y lme t h y l - 7 - [ 3 - ﬂuo r o - 4 -
(cyclopropylamino)phenyl][1,2,4]triazolo[4,3-a]pyridine (27).
Starting from 50a (0.30 g, 0.9 mmol) and 52i (0.3 g, 1.08 mmol) and
following the procedure described for 8, compound 27was obtained as a
white solid (0.147 g, 46%). 1H NMR (500 MHz, CDCl3) δ ppm 0.28−
0.40 (m, 2H), 0.57−0.69 (m, 4H), 0.78−0.87 (m, 2H), 1.15−1.28 (m,
1H), 2.45−2.56 (m, 1H), 3.11 (d, J = 6.65 Hz, 2H), 4.60 (br s, 1H), 6.88
(d, J = 7.22 Hz, 1H), 7.13−7.20 (m, 1H), 7.21−7.31 (m, 2H), 7.92 (d, J
= 6.94 Hz, 1H). LC−MS m/z 357 [M + H]+, tR = 3.30 min.
8-Triﬂuoromethyl-3-cyclopropylmethyl-7-[3-ﬂuoro-4-
(cyclopropylamino)phenyl][1,2,4]triazolo[4,3-a]pyridine (28).
Starting from 49a (0.20 g, 0.73 mmol) and 52i (0.221 g, 0.8 mmol)
and following the procedure described for 8, compound 28was obtained
as a white solid (0.169 g, 60%). Mp > 300 °C. 1H NMR (400 MHz,
CDCl3) δ ppm 0.28−0.43 (m, 2H), 0.51−0.72 (m, 4H), 0.75−0.91 (m,
2H), 1.12−1.31 (m, 1H), 2.50 (tt, J = 6.56, 3.27 Hz, 1H), 3.13 (d, J =
6.70 Hz, 2H), 4.58 (br s, 1H), 6.80 (d, J = 6.94 Hz, 1H), 6.98−7.09 (m,
2H), 7.10−7.18 (m, 1H), 8.05 (d, J = 7.17 Hz, 1H). LC−MS m/z 391
[M + H]+, tR = 3.18 min.
8-Triﬂuoromethyl-3-cyclopropylmethyl-7-[3-chloro-4-
(cyclopropylamino)phenyl][1,2,4]triazolo[4,3-a]pyridine (29).
Starting from 49a (0.20 g, 0.73 mmol) and 52j (0.34 g, 0.8 mmol)
and following the procedure described for 8, compound 29was obtained
as a white solid (0.109 g, 37%). 1H NMR (400 MHz, CDCl3) δ ppm
0.31−0.40 (m, 2H), 0.59−0.69 (m, 4H), 0.81−0.89 (m, 2H), 1.15−1.27
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(m, 1H), 2.46−2.56 (m, 1H), 3.13 (d, J = 6.70 Hz, 2H), 4.93 (s, 1H),
6.80 (d, J = 7.17 Hz, 1H), 7.11−7.16 (m, 1H), 7.17−7.23 (m, 1H), 7.28
(d, J = 1.85 Hz, 1H), 8.05 (d, J = 7.17 Hz, 1H). LC−MS m/z 407 [M +
H]+, tR = 3.48 min.
8 - Ch l o r o - 3 - c y c l op r o py lme t h y l - 7 - [ 3 - c h l o r o - 4 -
(cyclopropylamino)phenyl][1,2,4]triazolo[4,3-a]pyridine (30).
Starting from 50a (0.30 g, 0.9 mmol) and 52j (0.32 g, 1.08 mmol)
and following the procedure described for 8, compound 30was obtained
as a white solid (0.147 g, 46%). Mp > 300 °C. 1H NMR (500 MHz,
CDCl3) δ ppm 0.29−0.42 (m, 2H), 0.57−0.70 (m, 4H), 0.78−0.92 (m,
2H), 1.15−1.27 (m, 1H), 2.49−2.56 (m, 1H), 3.11 (d, J = 6.7 Hz, 2H),
4.60 (br s, 1H), 6.87 (d, J = 6.9Hz, 1H), 7.18 (d, J = 8.3Hz, 1H), 7.42 dd,
J = 8.3, 2.1 Hz, 1H), 7.47 (d, J = 1.8 Hz, 1H), 7.92 (d, J = 7.2 Hz, 1H).
LC−MS m/z 373 [M + H]+, tR = 3.83 min.
8-Triﬂuoromethyl-3-cyclopropylmethyl-7-{4-[(2-methoxy-
pyridin-5-yl)methoxy]-3-ﬂuorophenyl}[1,2,4]triazolo[4,3-a]-
pyridine (31). Starting from 49a (0.3 g, 1.088 mmol) and 52k (0.721 g,
1.306mmol) and following the procedure described for 8, compound 31
was obtained as a white solid (0.198 g, 38%). Mp 148.5 °C. 1H NMR
(400 MHz, CDCl3) δ ppm 0.37 (q, J = 5.09 Hz, 2H), 0.56−0.74 (m,
2H), 1.09−1.32 (m, 1H), 3.14 (d, J = 6.70 Hz, 2H), 3.96 (s, 3H), 5.12 (s,
2H), 6.79 (dd, J = 13.87, 7.63 Hz, 2H), 7.00−7.19 (m, 3H), 7.71 (dd, J =
8.55, 2.54 Hz, 1H) 8.09 (d, J = 7.17 Hz, 1H), 8.24 (d, J = 2.31 Hz, 1H).
LC−MS m/z 473 [M + H]+, tR = 2.79 min.
8-Triﬂuoromethyl-3-cyclopropylmethyl-7-{4-[(2-methoxy-
pyridin-5-yl)methoxy]phenyl}[1,2,4]triazolo[4,3-a]pyridine
(32). Starting from 49a (0.315 g, 1.15 mmol) and 52l (0.430 g, 1.26
mmol) and following the procedure described for 8, compound 32 was
obtained as a white solid (0.286 g, 60%). Mp 159.1 °C. 1H NMR (400
MHz, CDCl3) δ ppm 0.29−0.45 (m, 2H), 0.55−0.72 (m, 2H), 1.10−
1.33 (m, 1H), 3.14 (d, J = 6.70Hz, 2H), 3.96 (s, 3H), 5.04 (s, 2H), 6.67−
6.87 (m, 2H), 7.00−7.12 (m, 2H), 7.32 (d, J = 8.55 Hz, 2H), 7.70 (dd, J
= 8.55, 2.31 Hz, 1H), 8.08 (d, J = 7.17Hz, 1H), 8.25 (d, J = 2.31Hz, 1H).
LC−MS m/z 455 [M + H]+, tR = 3.73 min.
8-Triﬂuoromethyl-3-cyclopropylmethyl-7-{4-[(2-methoxy-
pyridin-5-yl)methylamino]-3-ﬂuorophenyl}[1,2,4]triazolo[4,3-
a]pyridine (33). Starting from 49a (0.530 g, 1.92 mmol) and 52m
(0.758 g, 2.11 mmol) and following the procedure described for 8,
compound 33 was obtained as a white solid (0.460 g, 51%). Mp 160.4
°C. 1H NMR (400MHz, CDCl3) δ ppm 0.30−0.42 (m, 2H), 0.59−0.71
(m, 2H), 1.15−1.27 (m, 1H), 3.13 (d, J = 6.70 Hz, 2H), 3.95 (s, 3H),
4.36 (d, J = 4.86Hz, 2H), 4.44 (br s, 1H), 6.69−6.83 (m, 3H), 6.95−7.12
(m, 2H), 7.62 (dd, J = 8.44, 2.43 Hz, 1H), 8.05 (d, J = 7.17 Hz, 1H), 8.19
(d, J = 2.54 Hz, 1H). LC−MS m/z 472 [M + H]+, tR = 2.67 min.
8-Triﬂuoromethyl-3-cyclopropylmethyl-7-{4-[(2-methoxy-
pyridin-5-yl)methylamino]-3-phenyl}[1,2,4]triazolo[4,3-a]-
pyridine (34). Starting from 49a (0.150 g, 0.544mmol) and 52n (0.204
g, 0.6 mmol) and following the procedure described for 8, compound 34
was obtained as a white solid (0.115 g, 46%). Mp 127.5 °C. 1H NMR
(500 MHz, CDCl3) δ ppm 0.29−0.42 (m, 2H), 0.60−0.68 (m, 2H),
1.17−1.24 (m, 1H), 3.12 (d, J = 6.94 Hz, 2H), 3.95 (s, 3H), 4.20 (br s,
1H), 4.32 (d, J = 4.91Hz, 2H), 6.70 (d, J = 8.38Hz, 2H), 6.76 (d, J = 8.38
Hz, 1H), 6.80 (d, J = 6.94 Hz, 1H), 7.21 (d, J = 8.67 Hz, 2H), 7.61 (dd, J
= 8.53, 2.46 Hz, 1H), 8.03 (d, J = 7.22Hz, 1H), 8.18 (d, J = 2.31Hz, 1H).
LC−MS m/z 454 [M + H]+, tR = 2.05 min.
8-Chloro-3-cyclopropylmethyl-7-{4-[(2-methoxypyridin-5-
yl)methylamino]-3-phenyl}[1,2,4]triazolo[4,3-a]pyridine (35).
Starting from 50a (0.150 g, 0.45 mmol) and 52n (0.168 g, 0.494
mmol) and following the procedure described for 8, compound 35 was
obtained as a white solid (0.098 g, 51%). Mp 158.1 °C. 1H NMR (400
MHz, CDCl3) δ ppm 0.30−0.40 (m, 2H), 0.57−0.70 (m, 2H), 1.13−
1.39 (m, 1H), 3.10 (d, J = 6.70Hz, 2H), 3.95 (s, 3H), 4.33 (s, 3H), 6.69−
6.79 (m, 3H), 6.89 (d, J = 7.17 Hz, 1H), 7.38−7.46 (m, 2H), 7.62 (dd, J
= 8.55, 2.54 Hz, 1H), 7.91 (d, J = 7.17Hz, 1H), 8.19 (d, J = 2.08Hz, 1H).
LC−MS m/z 420 [M + H]+, tR = 1.93 min.
8-Chloro-3-cyclopropylmethyl-7-[3-chloro-4-(tetrahydro-
pyran-4-yloxy)phenyl][1,2,4]triazolo[4,3-a]pyridine (36). Start-
ing from 50a (0.20 g, 0.6 mmol) and 52o (0.243 g, 0.72 mmol) and
following the procedure described for 8, compound 36was obtained as a
white solid (0.160 g, 64%). Mp 189.1 °C. 1H NMR (400 MHz, CDCl3)
δ ppm 0.30−0.43 (m, 2H), 0.56−0.73 (m, 2H), 1.15−1.30 (m, 1H),
1.92 (ddt, J = 17.05, 7.28, 3.55, 3.55 Hz, 2H), 2.02−2.17 (m, 2H), 3.12
(d, J = 6.70 Hz, 2H), 3.65 (ddd, J = 11.44, 7.40, 3.58 Hz, 2H), 4.05 (ddd,
J = 11.44, 7.40, 3.58 Hz, 2H), 4.66 (tt, J = 7.11, 3.64 Hz, 1H), 6.86 (d, J =
6.94 Hz, 1H), 7.06 (d, J = 8.55 Hz, 1H), 7.43 (dd, J = 8.55, 2.31 Hz, 1H),
7.58 (d, J = 2.31 Hz, 1H), 7.96 (d, J = 7.17 Hz, 1H). LC−MS m/z 418
[M + H]+, tR = 3.25 min.
8-Triﬂuoromethyl-3-cyclopropylmethyl-7-[3-chloro-4-(tetra-
hydropyran-4-yloxy)phenyl][1,2,4]triazolo[4,3-a]pyridine (37).
Starting from 49a (0.09 g, 0.33 mmol) and 52o (0.138 g, 0.41 mmol)
and following the procedure described for 8, compound 37was obtained
as a white solid (0.083 g, 56%). Mp 176.9 °C. 1H NMR (400 MHz,
CDCl3) δ ppm 0.30−0.43 (m, 2H), 0.58−0.73 (m, 2H), 1.16−1.28 (m,
1H), 1.86−1.97 (m, 2H), 2.02−2.12 (m, 2H), 3.14 (d, J = 6.70 Hz, H),
3.59−3.69 (m, 2H), 4−4.09 (m, 2H), 4.61−4.68 (m, 2H), 6.78 (d, J =
7.2 Hz, 1H), 7.02 (d, J = 8.6 Hz, 1H), 7.20 (dd, J = 8.6, 2.1 Hz, 1H), 7.41
(d, J = 2.1 Hz, 1H), 8.09 (d, J = 7.2 Hz, 1H). LC−MSm/z 452 [M+H]+,
tR = 3.33 min.
8-Chloro-3-cyclopropylmethyl-7-[3-chloro-4-(tetrahydro-
pyran-4-ylamino)phenyl][1,2,4]triazolo[4,3-a]pyridine (38).
Starting from 50a (0.20 g, 0.6 mmol) and 52p (0.242 g, 0.72 mmol)
and following the procedure described for 8, compound 38was obtained
as a white solid (0.160 g, 64%). Mp 221.3 °C. 1H NMR (500 MHz,
CDCl3) δ ppm 0.28−0.41 (m, 2H), 0.56−0.71 (m, 2H), 1.13−1.29 (m,
1H), 1.45−1.71 (m, 2H), 2.10 (br d, J = 13.29 Hz, 2H), 3.11 (d, J = 6.65
Hz, 2H), 3.52−3.60 (m, 2H), 3.62 (br dd, J = 6.94, 3.18 Hz, 1H), 4.05
(dt, J = 11.78, 3.65Hz, 2H), 4.49 (br d, J = 7.80Hz, 1H), 6.78 (d, J = 8.38
Hz, 1H), 6.86 (d, J = 7.22 Hz, 1H), 7.39 (dd, J = 8.53, 2.17 Hz, 1H), 7.51
(d, J = 2.31 Hz, 1H), 7.92 (d, J = 7.22 Hz, 1H). LC−MS m/z 417 [M +
H]+, tR = 4.08 min.
8-Triﬂuoromethyl-3-cyclopropylmethyl-7-[3-chloro-4-(tetra-
hydropyran-4-ylamino)phenyl][1,2,4]triazolo[4,3-a]pyridine
(39). Starting from 49a (0.07 g, 0.25 mmol) and 52p (0.107 g, 0.32
mmol) and following the procedure described for 8, compound 39 was
obtained as a white solid (0.045 g, 39%). Mp 198.4 °C. 1H NMR (400
MHz, CDCl3) δ ppm 0.31−0.42 (m, 2H), 0.58−0.71 (m, 2H), 1.16−
1.27 (m, 1H), 1.55−1.68 (m, 2H), 2.09 (br d, J = 12.7 Hz, 2H), 3.13 (d, J
= 6.7 Hz, 2H), 3.56 (td, J = 11.8, 2.3 Hz, 1H), 3.56−3.67 (m, 1H), 4.05
(dt, J = 11.7, 3.7 Hz, 2H), 4.47 (d, J = 7.6 Hz, 1H), 6.74 (d, J = 8.6 Hz,
1H), 6.78 (d, J = 7.2 Hz, 1H), 7.16 (dd, J = 8.3, 1.8 Hz, 1H), 7.32 (d, J =
2.1 Hz, 1H), 8.05 (d, J = 7.2 Hz, 1H). LC−MS m/z 451 [M + H]+, tR =
3.29 min.
8-Triﬂuoromethyl-3-cyclopropylmethyl-7-[3-chloro-4-(tetra-
hydropyran-4-ylaminomethyl)phenyl][1,2,4]triazolo[4,3-a]-
pyridine (40). Starting from 49a (0.2 g, 0.73 mmol) and 52q (0.306 g,
0.87 mmol) and following the procedure described for 8, compound 40
was obtained as a white solid (0.060 g, 18%). 1H NMR (400 MHz,
CDCl3) δ ppm 0.37 (q, J = 5.09 Hz, 2H), 0.59−0.74 (m, 2H), 1.10−1.32
(m, 2H), 1.41−1.73 (m, 2H), 1.92 (br dd, J = 12.60, 1.73Hz, 2H), 2.69−
2.86 (m, 1H), 3.15 (d, J = 6.70 Hz, 2H), 3.34−3.49 (m, 2H), 3.97−4.01
(m, 3H), 4.01−4.04 (m, 1H), 6.76 (d, J = 7.17 Hz, 1H), 7.22−7.28 (m,
1H), 7.37 (d, J = 1.62Hz, 1H), 7.56 (d, J = 7.86Hz, 1H), 8.10 (d, J = 7.17
Hz, 1H). LC−MS m/z 465 [M + H]+, tR = 2.09 min.
trans-8-Chloro-3-cyclopropylmethyl-7-[3-chloro-4-(4-
hydroxycyclohexylamino)phenyl][1,2,4]triazolo[4,3-a]pyridine
(41). Starting from 50a (0.13 g, 0.388 mmol) and 52r (0.15 g, 0.43
mmol) and following the procedure described for 8, compound 41 was
obtained as a white solid (0.087 g, 52%). Mp 270.9 °C. 1H NMR (400
MHz, CDCl3) δ ppm 0.29−0.42 (m, 2H), 0.56−0.71 (m, 2H), 1.17−
1.25 (m, 1H), 1.47 (br s, 1H), 1.73−1.8 (m, 4H), 1.80−1.91 (m, 4H),
3.11 (d, J = 6.7 Hz, 2H), 3.46−3.57 (m, 1H), 3.98 (br s, 1H), 4.60 (br d, J
= 7.6 Hz, 1H), 6.76 (d, J = 8.8 Hz, 1H), 6.87 (d, J = 7.2 Hz, 1H), 7.39
(dd, J = 8.3, 2.3 Hz, 1H), 7.49 (d, J = 2.1 Hz, 1H), 7.91 (d, J = 7.2 Hz,
1H). LC−MS m/z 431 [M + H]+, tR = 3.49 min.
trans-8-Triﬂuoromethyl-3-cyclopropylmethyl-7-[3-chloro-4-
(4-hydroxycyclohexylamino)phenyl][1,2,4]triazolo[4,3-a]-
pyridine (42). Starting from 49a (0.3 g, 1.088 mmol) and 52r (0.459 g,
1.306mmol) and following the procedure described for 8, compound 42
was obtained as a white solid (0.209 g, 41%). Mp 290.7 °C. 1H NMR
(400 MHz, CDCl3) δ ppm 0.3−0.43 (m, 2H), 0.58−0.71 (m, 2H),
1.16−1.25 (m, 1H), 1.29−1.42 (m, 2H), 1.42−1.53 (m, 3H), 2.03−2.12
(m, 2H), 2.20 (br d, J = 12.0 Hz, 2H), 3.13 (d, J = 6.7 Hz, 2H), 3.32−
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3.43 (m, 1H), 3.70−3.80 (m, 1H), 4.39 (d, J = 7.6 Hz, 1H), 6.72 (d, J =
8.6 Hz, 1H), 6.79 (d, J = 7.2 Hz, 1H), 7.16 (dd, J = 8.6, 2.1 Hz, 1H), 7.30
(d, J = 2.1Hz, 1H), 8.04 (d, J = 7.2Hz, 1H). LC−MSm/z 465 [M+H]+,
tR = 2.50 min.
cis-8-Chloro-3-cyclopropylmethyl-7-[3-chloro-4-(4-hydroxy-
cyclohexylamino)phenyl][1,2,4]triazolo[4,3-a]pyridine (43).
Starting from 50a (0.13 g, 0.388 mmol) and 52s (0.15 g, 0.43 mmol)
and following the procedure described for 8, compound 43was obtained
as a white solid (0.060 g, 36%). Mp 273.7 °C. 1H NMR (400 MHz,
CDCl3) δ ppm 0.27−0.43 (m, 2H) 0.57−0.70 (m, 2H), 1.02−1.32 (m,
2H), 1.68−1.98 (m, 8H), 3.11 (d, J = 6.70 Hz, 2H), 3.44−3.62 (m, 1H),
3.98 (br s, 1H), 4.60 (br d, J = 7.63 Hz, 1H), 6.76 (d, J = 8.79 Hz, 1H),
6.87 (d, J = 7.17 Hz, 1H), 7.39 (dd, J = 8.44, 2.20 Hz, 1H), 7.49 (d, J =
2.08Hz, 1H), 7.91 (d, J = 7.17Hz, 1H). LC−MSm/z 431 [M+H]+, tR =
3.08 min.
cis-8-Triﬂuoromethyl-3-cyclopropylmethyl-7-[3-chloro-4-(4-
hydroxy-4-cyclopropylcyclohexylamino)phenyl][1,2,4]-
triazolo[4,3-a]pyridine (44). Starting from 49a (0.143 g, 0.52 mmol)
and 52t (0.235 g, 0.6 mmol) and following the procedure described for
8, compound 44 was obtained as a white solid (0.047 g, 18%). Mp > 300
°C. 1H NMR (500MHz, CDCl3) δ ppm 0.04−0.16 (m, 2H), 0.18−0.33
(m, 5H), 0.34−0.43 (m, 2H), 0.60 (tt, J = 8.31, 5.56 Hz, 1H), 0.80−1.00
(m, 1H), 1.11−1.25 (m, 2H), 1.31−1.56 (m, 4H), 1.63−1.79 (m, 2H),
2.49 (d, J = 6.65 Hz, 2H), 2.97 (tdt, J = 11.13, 11.13, 7.37, 3.97, 3.97 Hz,
1H), 4.45 (d, J = 7.51Hz, 1H), 5.95 (d, J = 7.22Hz, 1H), 6.53 (d, J = 8.67
Hz, 1H), 6.73 (d, J = 7.22 Hz, 1H), 7.16 (s, 1H) 7.28 (d, J = 2.02 Hz,
1H). LC−MS m/z 465 [M + H]+, tR = 3.49 min.
trans-8-Chloro-3-(2,2,2-triﬂuoroethyl)-7-[3-chloro-4-(4-
hydroxycyclohexylamino)phenyl][1,2,4]triazolo[4,3-a]pyridine
(45). Starting from 56c (0.11 g, 0.304 mmol) and 52r (0.128 g, 0.365
mmol) and following the procedure described for 8, compound 45 was
obtained as a white solid (0.054 g, 39%). Mp > 300 °C. 1H NMR (400
MHz, CDCl3) δ ppm 1.28−1.52 (m, 5H), 2.08 (br d, J = 10.63 Hz, 2H),
2.20 (br d, J = 12.02 Hz, 2H), 3.26−3.46 (m, 1H), 3.62−3.85 (m, 1H),
4.08 (q, J = 9.71 Hz, 2H), 4.44 (d, J = 7.63 Hz, 1H), 6.77 (d, J = 8.55 Hz,
1H), 6.97 (d, J = 7.17Hz, 1H), 7.39 (dd, J = 8.55, 2.08Hz, 1H), 7.50 (d, J
= 2.08Hz, 1H), 7.94 (d, J = 7.17Hz, 1H). LC−MSm/z 459 [M+H]+, tR
= 3.23 min.
trans-8-Triﬂuoromethyl-3-cyclopropylmethyl-7-[3-chloro-4-
(4-hydroxycyclohexyloxy)phenyl][1,2,4]triazolo[4,3-a]pyridine
(46). Starting from 49a (0.119 g, 0.432 mmol) and 52u (0.183g, 0.518
mmol) and following the procedure described for 8, compound 46 was
obtained as a white solid (0.022 g, 27%). 1HNMR (400MHz, CDCl3) δ
ppm 0.31−0.41 (m, 2H), 0.61−0.71 (m, 2H), 1.09−1.32 (m, 2H),
1.42−1.56 (m, 2H), 1.67−1.80 (m, 2H), 2.05−2.23 (m, 4H), 3.14 (d, J =
6.70 Hz, 2H), 3.83−3.96 (m, 1H), 4.36−4.49 (m, 1H), 6.78 (d, J = 7.17
Hz, 1H), 7.02 (d, J = 8.79 Hz, 1H), 7.20 (dd, J = 8.44, 2.20 Hz, 1H), 7.39
(d, J = 2.31 Hz, 1H), 8.09 (d, J = 7.17 Hz, 1H). LC−MS m/z 466 [M +
H]+, tR = 2.96 min.
trans-8-Chloro-3-(2,2,2-triﬂuoroethyl)-7-[3-chloro-4-(4-
hydroxycyclohexyloxy)phenyl][1,2,4]triazolo[4,3-a]pyridine
(47). Starting from 56c (0.190 g, 0.526 mmol) and 52u (0.222 g, 0.631
mmol) and following the procedure described for 8, compound 47 was
obtained as a white solid (0.065 g, 27%). Mp > 300 °C. 1H NMR (500
MHz, CDCl3) δ ppm 1.42 (d, J = 3.76 Hz, 1H), 1.46−1.55 (m, 2H),
1.68−1.79 (m, 2H), 2.10 (td, J = 7.73, 3.61 Hz, 2H), 2.18 (td, J = 7.66,
3.47 Hz, 2H), 3.91 (td, J = 8.09, 4.05 Hz, 1H), 4.10 (q, J = 9.73 Hz, 2H),
4.46 (tt, J = 8.06, 3.79 Hz, 1H), 6.97 (d, J = 7.22 Hz, 1H), 7.08 (d, J =
8.38 Hz, 1H), 7.42 (dd, J = 8.53, 2.17 Hz, 1H), 7.57 (d, J = 2.31 Hz, 1H),
7.98 (d, J = 7.22 Hz, 1H). LC−MS m/z 460 [M + H]+, tR = 3.23 min.
cis-8-Chloro-3-(2,2,2-triﬂuoroethyl)-7-[3-chloro-4-(4-
hydroxycyclohexyloxy)phenyl][1,2,4]triazolo[4,3-a]pyridine
(48). Starting from 56c (0.150 g, 0.415 mmol) and 52v (0.176g, 0.498
mmol) and following the procedure described for 8, compound 48 was
obtained as a white solid (0.044 g, 23%). Mp 196.7 °C. 1H NMR (400
MHz, CDCl3) δ ppm 1.39−1.48 (m, 1H), 1.66−1.93 (m, 6H), 2.06−
2.21 (m, 2H), 3.81 (tq, J = 8.44, 4.24 Hz, 1H), 4.10 (q, J = 9.71 Hz, 2H),
4.56 (tt, J = 5.20, 2.77 Hz, 1H), 6.98 (d, J = 7.17 Hz, 1H), 7.06 (d, J =
8.55 Hz, 1H), 7.43 (dd, J = 8.55, 2.31 Hz, 1H), 7.57 (d, J = 2.31 Hz, 1H),
7.99 (d, J = 7.17 Hz, 1H). LC−MS m/z 460 [M + H]+, tR = 3.14 min.
8-Triﬂuoromethyl-3-(ethoxymethyl)-7-[3-chloro-1,2,4-
triazolo[4,3-a]pyridine (49b). Mp 104 °C. 1H NMR (400 MHz,
CDCl3) δ ppm 1.22 (t, J = 6.94 Hz, 3 H), 3.57 (q, J = 6.94 Hz, 2 H), 5.08
(s, 2 H), 6.95 (d, J = 7.22 Hz, 1 H), 8.35 (d, J = 7.51 Hz, 1 H). LC−MS
m/z 280 [M + H]+, tR = 1.32 min.
Biology. Membrane Preparation. CHO-K1 cells stably expressing
the wild-type hmGlu2 receptor (CHO-K1_hmGlu2) were grown in
DMEMmedium supplemented with 10% (v/v) fetal calf serum, 200 IU/
mL penicillin, 200 μg/mL streptomycin, 30.5 μg/mL L-proline, and 400
μg/mL G418 at 37 °C and 5% CO2. Sodium butyrate (ﬁnal
concentration 5 mM) was added to the plates when cells growth
reached 70% conﬂuency.63 24 h later, cells were detached from the plates
by scraping them into 5 mL of PBS and were centrifuged for 5 min at
1500 rpm. Pellets were resuspended into ice-cold Tris buﬀer (50 mM
Tris-HCl, pH 7.4) and homogenized using an Ultra Turrax
homogenizer (IKA Werke GmbH & Co.KG, Staufen, Germany). An
Optima LE 80 K ultracentrifuge (Beckman Coulter, Fullerton, CA) at
31 000 rpm was used for separation of membranes and the cytosolic
fraction at 4 °C for 20 min. Pellets were resuspended in 10 mL of Tris
buﬀer, and the centrifugation and homogenization steps were repeated.
Remaining pellets were suspended into assay buﬀer (50 mM Tris-HCl,
pH 7.4, 2 mMCaCl2, 10 mMMgCl2), and the homogenization step was
repeated. Aliquots were stored at −80 °C. BCA protein determination
was used to determine the membrane protein concentrations.
[35S]GTPγS Binding Assay. [35S]GTPγS binding experiments were
performed as previously described.12
Radioligand Binding Assays. After thawing, membranes were
homogenized by an Ultra Turrax homogenizer. 4 (10 μM) was used
to determine nonspeciﬁc binding. DMSO concentrations were ≤0.25%.
For all experiments, radioligand concentrations were such that <10% of
the amount added was receptor-bound to avoid ligand depletion.
For displacement assays, membrane protein aliquots (30 μg) were
incubated with 6 nM [3H]-7 and 10 concentrations of competing ligand
diluted by an HP D300 digital dispenser (Tecan, Giessen, The
Netherlands) in assay buﬀer to a total volume of 100 μL. After 60 min at
15 °C, incubation was terminated by rapid ﬁltration over GF/C ﬁlter
plates (PerkinElmer, Groningen, The Netherlands) on a PerkinElmer
Filtermate harvester. Filter plates were washed 10 times with ice-cold
wash buﬀer (50 mM Tris-HCl, pH 7.4), and ﬁlter-bound radioactivity
was determined in a Microbeta 24502 microplate counter (PerkinElm-
er).
For association, dissociation, and competition association experi-
ments a scintillation proximity assay (SPA) was developed and used.
Membrane protein (20 μg) and prewetted wheat-germ agglutinin
coated SPA beads (0.2 mg; RPNQ0001, PerkinElmer) were precoupled
in assay buﬀer while gently shaking at room temperature for 30 min.
Then, this membrane bead mixture was added to an Isoplate-96
(PerkinElmer) together with 6 nM [3H]-7 and competing ligand in case
of competition association. After addition, the plate was rapidly placed in
aMicrobeta 24502 microplate counter. Plates were recorded for 120 min
measuring every 30 s at ambient temperature of 28 °C. Binding values
were determined in corrected counts per minute (CCPM). For
dissociation assays, radioligand dissociation was initiated after 60 min
of incubation by addition of 5 μL of 4 (ﬁnal concentration: 10 μM).
Subsequently, plates were recorded for 120 min being measured every
30 s.
Label-Free Whole-Cell Assays. Label-free whole-cell assays were
performed using the xCELLigence real-time cell analyzer (RTCA DP)
system as described previously.58,64 Baseline impedance was measured
using 45 μL of culture medium (as described under membrane
preparation) per well in 16-well E-plates (Westburg, Leusden, The
Netherlands). 40 000 cells per well were added in a volume of 50 μL.
After resting for 30 min at room temperature, E-plates were placed in the
recording station within a humidiﬁed 37 °C, 5% CO2 incubator.
Impedance (represented in the arbitrary unit cell index) was measured
every 15 min overnight. After 18 h, cells were stimulated with the
indicated concentration of compound. Impedance was measured every
15 s for 20 min, then 5 min intervals were used for the next 40 min,
followed by 15 min intervals thereafter. For washing experiments, cells
were stimulated with an EC80 equivalent concentration of compound in
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a volume of 5 μL. Wells were washed after 5 min by aspiration of the
medium, addition of 100 μL of fresh medium, which was subsequently
aspirated and replaced by another 100 μL of freshmedium. This washing
step was chosen such that it was just before the maximum cell index
level. In control wells, medium was pipetted up and down in order to
induce similar mechanical cell stress.
Data Analysis. Data analyses were performed using Prism 6.04
(GraphPad software, San Diego, CA, USA). pIC50 values were acquired
using nonlinear regression curve ﬁtting into a sigmoidal concentration−
response curve using the equation: Y = Bottom + (Top− Bottom)/(1 +
10(X−log IC50)). (p)Ki values were acquired from (p)IC50 values using the
Cheng−Prusoﬀ equation.65 Dissociation rate constants koff were
determined using an exponential decay analysis of radioligand binding.
Association rate constants kon were determined using the equation kon =
(kobs − koff)/[L], in which L is the concentration of radioligand used for
association experiments and kobs was determined using exponential
association analysis.
Association and dissociation rate constants for unlabeled mGlu2
PAMs were determined by nonlinear regression analysis of competition
association data as described by Motulsky and Mahan.40
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Experimental data are reported as kon and koff, and the corresponding
conversion of koff to residence time (RT) is performed to be consistent
with current state of the art.24
Data shown are the mean ± SEM of at least three individual
experiments performed in duplicate unless stated otherwise. Statistical
analysis was performed if indicated, using a two-tailed unpaired
Student’s t test. Observed diﬀerences with p-values of <0.05 were
considered statistically signiﬁcant. clogP values were calculated using
ChemDraw Professional version 15.0.0.106 (PerkinElmer).
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time; SEM, standard error of the mean; SPA, scintillation
proximity assay; VFT, Venus ﬂytrap domain; 7TM, seven
transmembrane domain
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